About Event
Struggling with Medical Affairs Challenges in Cell & Gene Therapy? We Get It.
Bringing next-gen therapies to life is no easy feat, especially when you're up against increasingly complex medical landscape. We know the obstacles you face—because we've seen them before—and we're ready to help your company conquer them.
Having trouble communicating your therapy's value to a growing list of stakeholders?
Feeling the pressure to better align your medical affairs team with other departments to ensure product safety and regulatory success?
Unsure how to demonstrate the real-world impact of your treatments in a way that resonates with decision-makers?
You're not alone. The Cell & Gene Therapy Medical Affairs Summit is where you'll find the strategies and solutions to move past these roadblocks
Ready to overcome these challenges?
Join Fellow Medical Affairs Experts to:
 |
Learn from the key challenges faced and overcome during the launch of commercialized cell and gene therapies to avoid repeating the same mistakes, following the examples set by Bristol Myers Squibb, bluebird bio, and Orchard Therapeutics |
|
Promote early involvement of medical affairs teams in product development to greatly enhance later success, emphasizing the value of effective onboarding as shown by Editas Medicine, ImmPACT Bio, and Vor Bio |
|
Foster cross-functional collaboration and trust-based relationships with R&D, clinical, market access, and commercial teams to boost patient and business outcomes, as demonstrated by Autolus Therapeutics and Tenaya Therapeutics |
|
Embed patient-centered thinking throughout the drug development life cycle, from pre-clinical to commercial, to successfully launch new modalities or target new populations, as exemplified by Adaptimmune and Alexion Biopharmaceuticals |
Download the Full Agenda for More Information on:
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
- 2 Interactive Deep-Dive Workshops
- 8+ Hours of Industry Networking
- 20+ Medical Affairs Speakers
- & Much More!
-
-
-
-
-
-
-
-
-
-
-
-
-
-
